According to statistics, the phenomenon of irregular drug withdrawal is common among hepatitis B patients, leading to the recurrence of hepatitis B status quo more serious. For a variety of reasons, adherence to long-term antiviral therapy is not an easy task, such as patients with medication to eat and stop, or due to the feeling of obvious symptoms, economic reasons and so on and stop the medication of a minority of people. The results of a research on patient adherence found that 63% of chronic hepatitis B patients had stopped taking oral antiviral drugs, and 57% of them had worsened conditions after stopping the drugs, such as liver failure, cirrhosis, and even hepatocellular carcinoma. The reason for the recurrence of hepatitis B due to irregular stopping of medication The fundamental reason for the recurrence of hepatitis B is that the hepatitis B virus continues to replicate. Since all oral antiviral drugs are designed to reduce disease progression by inhibiting viral replication over a long period of time, the cccDNA, which is the template for hepatitis B virus replication located in the nucleus of hepatocytes, can not be completely eliminated, so after stopping the drugs, the hepatitis B virus may continue to replicate and lead to the recurrence of hepatitis B. Some data show that the relapse rate of oral antiviral drugs currently used in clinical practice is more than 50% after stopping the drugs. The complexity of retreatment for patients with hepatitis B relapse after discontinuation of medication is increased compared to that of patients on initial treatment. First, patients who relapse have been treated with antiviral therapy, many with at least one oral antiviral drug, and some have developed resistance or are at risk of resistance, requiring individualized regimens based on past medical history. In addition, relapsed patients are less confident and less compliant when they return to treatment, and it takes a lot of time and effort for doctors to convince patients to start treatment again. In addition to the increased complexity of treatment, hepatitis B recurrence retreatment also differs from primary treatment in terms of treatment strategy. Most experts agree that standardized treatment is the key to hepatitis B recurrence, and there are two main treatment strategies: one is to choose a combination of two oral antiviral drugs that do not have cross-resistance sites (e.g., lamivudine plus adefovir); and the other is to switch to an oral antiviral drug that does not have cross-resistance sites to the previous drug according to the history of the previous medication (e.g., switching to entecavir with adefovir). Regular testing of liver function and viral load to prevent recurrence of hepatitis B Regular testing is important for both patients who are on treatment and those who have stopped taking medication, so that patients can have a clear understanding of their condition, while doctors can formulate a treatment plan in a targeted manner. For different hepatitis B patients, it is recommended as follows: First, for hepatitis B patients on oral antiviral therapy, it should be known that irregular discontinuation of medication may increase the risk of relapse, for example, patients older than 40 years old have been infected with hepatitis B virus for a relatively long time, and if the time for consolidation of treatment is not enough, it is easy to relapse after discontinuation of medication; second, for e-antigen-negative patients, the rate of relapse after discontinuation of medication is also relatively high. Thirdly, it is recommended that hepatitis B patients who are on oral antiviral therapy should adhere to long-term and standardized treatment, and should not stop taking medication easily. Fourthly, for patients with hepatitis B who have already relapsed, they should not blame the relapse on the treatment drugs, but should set up the confidence of overcoming the disease, knowing that long-term antiviral treatment is the key to hepatitis B treatment, and should actively start standardized antiviral treatment again. In addition, they should take the initiative to fully communicate with their doctors about their past drug history, treatment effect, and drug discontinuation, so that the doctors can formulate targeted and individualized re-treatment plans.